Benzinga Rankings give you vital metrics on any stock – anytime.
You can purchase shares of Apimeds Pharmaceuticals (AMEX:APUS) through any online brokerage.
Other companies in Apimeds Pharmaceuticals’s space includes: Intensity Therapeutics Inc (NASDAQ:INTS), Lunai Bioworks Inc (NASDAQ:LNAI), Nanoviricides Inc (AMEX:NNVC), Barinthus Biotherapeutics PLC (NASDAQ:BRNS) and CollPlant Biotechnologies Ltd (NASDAQ:CLGN).
There is no analysis for Apimeds Pharmaceuticals to provide a consensus price target.
The stock price for Apimeds Pharmaceuticals (AMEX: APUS) is $2.14 last updated December 15, 2025 at 8:55 AM EST.
There are no upcoming dividends for Apimeds Pharmaceuticals.
Apimeds Pharmaceuticals does not have any upcoming earnings scheduled.
There is no upcoming split for Apimeds Pharmaceuticals.
Apimeds Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.